[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100642259":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":40,"centralContacts":48,"locations":54,"responsibleParty":77,"collaborators":30,"id":79,"slug":80,"hasResults":81,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":30,"eligibilityCriteria":85,"healthyVolunteers":81,"sex":86,"minAge":87,"maxAge":88,"enrollmentInfo":89,"targetDuration":30,"studyType":92,"phases":93,"briefSummary":95,"conditions":96,"keywords":98,"overallStatus":57,"whyStopped":30,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":109},{"fullName":5,"class":6},"Damascus University","OTHER",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Arm 1: Clobetasol propionate 0.05% Mouthwash","EXPERIMENTAL","Drug: Clobetasol propionate 0.05% mouthwash\n\n* Use 3 times daily.\n* Rinse and hold in the mouth for 3 minutes per application.\n* Do not swallow.\n* Duration: 4 weeks. Follow-up instructions: After 4 weeks of therapy, if the patient achieves complete clinical remission, taper the frequency gradually until discontinuation, similar to the tapering of systemic steroids (e.g., reduce from three times daily → twice daily → once daily → every other day → stop).",[13],"Drug: Clobetasol propionate 0.05% Mouthwash",{"label":15,"type":10,"description":16,"interventionNames":17},"Arm 2: Photobiomodulation Therapy","Patients in the laser group received photobiomodulation therapy using a 650 nm diode laser (continuous wave mode). The laser parameters were as follows:\n\n* Wavelength: 650 nm\n* Output power: 100 mW\n* Mode: Continuous wave\n* Radiant exposure (energy density): 4 J\u002Fcm² per session\n* Exposure duration: 20 seconds per session (adjusted according to the spot size\u002Farea of the lesion to achieve the target fluence of 4 J\u002Fcm²) Treatment was applied without contact by maintaining a distance of 1 mm from the lesion and making continuous circular movements from the periphery toward the center of the lesions. Sessions were performed twice a week for a total duration of 30 days (approximately 8-9 sessions, depending on the exact scheduling).",[18],"Device: diode laser for photobiomodulation",{"label":20,"type":10,"description":21,"interventionNames":22},"Arm 3: Combination Therapy","All patients in the intervention arm received combined treatment consisting of:\n\nClobetasol propionate 0.05% mouthwash, rinsed three times daily for 3 minutes each time, for 30 days, in addition to photobiomodulation therapy using a 650 nm diode laser (continuous mode, 100 mW, 4 J\u002Fcm², 20 seconds per session). The laser therapy was administered twice weekly for 30 days. Treatments were performed by a trained clinician according to standardized protocol.",[13,23],"Drug: clobetasol propionate 0.05% mouthwash + photobiomodulation",[25,31,36],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"DRUG","Clobetasol propionate 0.05% Mouthwash","Participants will receive topical clobetasol propionate 0.05% mouthwash",[9,20],null,{"type":32,"name":33,"description":34,"armGroupLabels":35,"otherNames":30},"DEVICE","diode laser for photobiomodulation","Participants will receive photobiomodulation therapy (low-level laser therapy) by diode laser.",[15],{"type":26,"name":37,"description":38,"armGroupLabels":39,"otherNames":30},"clobetasol propionate 0.05% mouthwash + photobiomodulation","Participants will receive combined treatment with topical clobetasol propionate 0.05% mouthwash and photobiomodulation therapy (low-level laser therapy) by diode laser.",[20],[41,45],{"name":42,"affiliation":43,"role":44},"Abeer Aljoujou, PhD In Oral medicine","Associate Professor, Department of Oral Medicine, Faculty of Dental medicine, Damascus University, Damascus, Syria.","PRINCIPAL_INVESTIGATOR",{"name":46,"affiliation":47,"role":44},"Nemat Alsaghir, PhD in dermatology","Lecturer, Department of Dermatology, Faculty of Medicine, Damascus University, Damascus, Syria.",[49],{"name":50,"role":51,"phone":52,"phoneExt":30,"email":53},"Alaa Alhomsi, DDS,MSc,PhD Student","CONTACT","00963993837778","allaalhomsi1@gmail.com",[55],{"facility":56,"status":57,"city":58,"state":30,"zip":30,"country":59,"countryCode":30,"cosmosGeoPoint":60,"geoPoint":65,"contacts":66},"Department of Oral Medicine, Faculty of Dental medicine","RECRUITING","Damascus","Syria",{"type":61,"coordinates":62},"Point",[63,64],36.29128,33.5102,{"lat":64,"lon":63},[67,71,74,75],{"name":68,"role":51,"phone":69,"phoneExt":30,"email":70},"Abeer Aljoujou, PhD in oral medicine","00963944703131","abeerjoujou@gmail.com",{"name":72,"role":73,"phone":30,"phoneExt":30,"email":30},"Alaa Alhomsi, Phd student in oral medicine","SUB_INVESTIGATOR",{"name":42,"role":44,"phone":30,"phoneExt":30,"email":30},{"name":76,"role":44,"phone":30,"phoneExt":30,"email":30},"Nemat Alsaghir, Phd in Dermatology",{"type":78,"investigatorFullName":30,"investigatorTitle":30,"investigatorAffiliation":30,"oldNameTitle":30,"oldOrganization":30},"SPONSOR","100642259","comparison-of-the-efficacy-of-clobetasol-propionate-005-mouthwash-photobiomodulation-and-their-combination-in-managing-of-oral-lesions-in-patient-with-pemphigus-vulgaris-100642259",false,"NCT07641725","Comparison of the Efficacy of Clobetasol Propionate 0.05% Mouthwash, Photobiomodulation, and Their Combination in Managing of Oral Lesions in Patient With Pemphigus Vulgaris.","Evaluation of the Effectiveness of Clobetasol Propionate 0.05% and Photobiomodulation in the Management of Oral Lesions in Patients With Pemphigus Vulgaris. (Three-arm Randomized Controlled Clinical Study)","Inclusion Criteria:\n\n1. Confirmed diagnosis of Pemphigus Vulgaris based on clinical presentation, histopathology, and immunopathological findings (positive direct and indirect immunofluorescence), according to World Health Organization (WHO) standards.\n2. Presence of active erosive or ulcerative oral lesions with a maximum diameter exceeding 1 cm.\n3. Patients currently maintained on a stable systemic corticosteroid regimen not exceeding 1 mg\u002Fkg\u002Fday.\n\nExclusion Criteria:\n\n1. Co-existing chronic systemic conditions, including significant gastrointestinal disorders or uncontrolled diabetes mellitus.\n2. History or current evidence of malignancy.\n3. Concurrent use of systemic antibiotics, non-steroidal anti-inflammatory drugs (NSAIDs), or hormonal therapies that may interfere with the study outcomes.\n4. Pregnancy or active lactation. Note: These criteria are strictly enforced to ensure that the study population remains homogeneous regarding the systemic treatment protocol.","ALL","18 Years","80 Years",{"count":90,"type":91},30,"ESTIMATED","INTERVENTIONAL",[94],"NA","Pemphigus vulgaris (PV) is a chronic, potentially life-threatening autoimmune mucocutaneous disorder that significantly impairs patients' quality of life. While systemic corticosteroids and immunosuppressants remain the standard of care, many patients suffer from persistent, painful oral lesions that exhibit delayed healing or poor response to conventional systemic protocols. This clinical trial investigates the efficacy and safety of supportive topical interventions: clobetasol propionate 0.05% mouthwash and photobiomodulation therapy (PBMT)-a non-invasive approach designed to accelerate tissue repair, and their combination. The primary objective is to identify effective adjunctive topical therapies that can facilitate the healing of oral erosions, mitigate pain, and potentially allow for a reduction in systemic medication dosages, thereby minimizing long-term treatment-related complications and improving overall patient outcomes.",[97],"Oral Lesions in Patients With Pemphigus Vulgaris",[99],"Pemphigus vulgaris - Photobiomodulation - Clobetasol propionate - Autoimmune Blistering Diseases.","2026-06-08",{"date":102,"type":103},"2026-06-11","ACTUAL",{"date":105,"type":103},"2025-11-01",{"date":107,"type":91},"2026-12-01",{"name":5,"class":6},1]